naulicreative / Shutterstock.com
The consequences of the Brexit vote for the life sciences sector will depend on the UK’s relationship with the EU once the negotiations are concluded, as Christina Guazzi and Nina Schäffner of Freshfields Bruckhaus Deringer explain.
One potential outcome of the British vote to leave the EU is the divergence of regulatory frameworks for bringing pharmaceutical products to market in the UK and the EU—UK IP rights may split from harmonised EU systems of protection.
UK life sciences companies will be hit hardest by these changes but they are also set to affect all major EU and international players with activities across the UK and the EU.
Of course, much will depend on the UK’s relationship with the EU once Brexit negotiations are concluded. If the UK remains in the European Economic Area (EEA), then the adjustments for the pharmaceutical industry are likely to be less significant.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Christina Guazzi, Nina Schäffner, Freshfields Bruckhaus Deringer, S[Cs, EEA, Brexit, life sciences, UPC, market exclusivity, EMA, MHRA, patent,